Check patentability & draft patents in minutes with Patsnap Eureka AI!

Assembly for extracorporeal treatment of bodily fluids

A technology of body fluids and binders, which can be applied to medical devices, other medical devices, and blood circulation treatment, etc. It can solve the problems of inconclusive sepsis experiments and difficult timing of intervention, and achieve the effect of gentle removal

Pending Publication Date: 2022-05-13
埃莫图内股份公司
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Heterogeneous disease stages in patients admitted to the intensive care unit, rapid disease progression in sepsis, and lack of thorough patient characterization make timing of intervention very difficult, leading to inconclusive sepsis trials

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Assembly for extracorporeal treatment of bodily fluids
  • Assembly for extracorporeal treatment of bodily fluids
  • Assembly for extracorporeal treatment of bodily fluids

Examples

Experimental program
Comparison scheme
Effect test

Embodiment A

[0086] Example A: Removal of Excessive Inflammatory Mediators

[0087] In the case of concentration sickness, the response according to the first model A is rapidly pro-inflammatory and anti-inflammatory. Severe sepsis is characterized by an overwhelmingly hyperinflammatory phase, including fever and abnormal increases in circulating volume, leading to septic shock. Cardiovascular failure, metabolic derangement, and multiple organ dysfunction are the main causes of death in such severe septic shock cases. Treatment consists of short-acting therapy with anti-inflammatory or anti-cytokine agents.

[0088] In patient A, as in Figure 1A Excessive inflammation was suspected following standard checks and according to the Surviving Sepsis Campaign, following pathogenic insult, as shown. The primary infection was identified as a Gram-negative infection. Based on this diagnosis, LPS and proinflammatory cytokines (early proinflammatory cytokines IL-1, TNFα and IL-18) are removed fro...

Embodiment B

[0092] Example B: Removal of Immunosuppressive Mediators

[0093] Comorbidities, especially in elderly patients, may impair the immune response. In patients responding according to this second model B, the development of sepsis can lead to a reduction or absence of the hyperinflammatory phase, and rapid development of an anti-inflammatory state. In this case, immune adjuvant therapy is used as the treatment of choice.

[0094] In patient B, the primary infection was identified as a Gram-positive infection. Following pathogenic insult, Patient B may have a normal inflammatory phase followed by an immunosuppressive phase (as indicated). However, similar to patient A, it is also possible that the patient first exhibited a hyperinflammatory phase (not shown in panel B). Depletion of lipoteichoic acid and pro-inflammatory cytokines from the blood in the extracorporeal treatment according to the invention, based on the diagnosis of Gram-positive infection, after standard examin...

Embodiment C

[0098] Example C: Restoring the Balance of the Immune Response

[0099] A third model C of a possible immune response to sepsis shows cycles between hyper-inflammatory and hypo-inflammatory or immunosuppressive states. If such patients develop sepsis, they show an initial hyperinflammatory response followed by a hypoinflammatory state and / or an immunosuppressive phase. In the setting of secondary infection, such patients may experience repeated hyperinflammatory responses leading to recovery or re-entry into a hypoinflammatory phase, with the risk of severe immunosuppression.

[0100] In patient C, as Figure 1C Excessive inflammation was detected after standard checks and according to the Surviving Sepsis Campaign, as shown. The primary infection was identified as a Gram-negative infection. Based on this diagnosis, LPS and proinflammatory cytokines (early proinflammatory cytokines IL-1 with short circulation time, TNFα and IL-18) are removed from the blood in an in vitro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for in vitro treatment of a bodily fluid of a patient suffering from an immune response of a sepsis disorder in an in vitro flow line, said method comprising removal of at least one hazardous substance from the bodily fluid of a patient suffering from an immune response disorder. The method comprises at least a first injection step in which a first mixture is added via a first injection device to an extracorporeal flow line comprising a sample of bodily fluid extracted from a patient and containing at least a first type of target molecules, the first mixture comprises functionalized magnetic particles bound to at least a first binding agent for at least a first type of target molecule comprised in a bodily fluid. The first mixture is injected at a therapeutically effective dose required to reduce the concentration of at least a first type of target molecule in a sample of a bodily fluid of the patient followed by a mixing step and a separation step for reducing the concentration of the target molecule.

Description

technical field [0001] The present invention relates to an ex vivo method for the in vitro treatment of a body fluid of a patient with a dysregulated immune response, in particular with sepsis, which method comprises the removal of at least one harmful substance from a sample of the patient's body fluid. Background technique [0002] Sepsis, a severe infection-related multiple organ dysfunction, has become the most common cause of death in hospitalized patients in the 21st century. Sepsis is a multistep process involving an uncontrolled inflammatory response of host cells that can lead to multiorgan failure and death. Unlike other major prevalent diseases, treatment of sepsis has so far been nonspecific and largely limited to support of organ function and administration of intravenous fluids, antibiotics and oxygen. There are no approved drugs specifically for sepsis. Significant costs are incurred due to the prolonged stay of septic patients in the intensive care unit. I...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61M1/34A61M1/36
CPCA61M1/3475A61M1/3486A61M1/342A61M1/3679A61M2205/3303A61M2205/0277A61B5/412
Inventor 卢卡斯·兰格内格卡洛斯·莫拉让-克劳德·梅茨格乌西娜·哈尔廷纳
Owner 埃莫图内股份公司
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com